A randomised, double-blind, multicentre study was performed to compare the effects of moclobemide and amineptine in the treatment of endogenous depression in out-patients. Ninety patients received moclobemide, 450 mg/day and 94 received amineptine 200 mg/day in two parallel groups, over a trial period of 8 weeks. At the end of 4 weeks doses could be reduced to 300 mg/day, moclobemide and 100 mg/day, amineptine if required. All evaluated patients showed a significant clinical improvement during treatment, but no significant difference occurred between the groups. When patients were asked to assess the benefit of their treatment, 76% thought their condition had improved following moclobemide therapy, compared to 53% of those receiving amineptine. Both drugs were well tolerated, and over 60% of patients reported no side-effects. Moclobemide appeared to be as effective as amineptine in the treatment of these patients, and was significantly better tolerated.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
About this article
Cite this article
Macher, J.P., Mirabaud, C. A double-blind comparison of moclobemide and amineptine in the treatment of depressed out-patients. Psychopharmacology 106, S116–S117 (1992). https://doi.org/10.1007/BF02246252
- Double-blind study